Würzburg
Pharmaceutical Screening in vestibular schwannoma ex vivo tumor slice model
Tumormicroenvironment in Vestibular schwannoma with and without NF2
Metastasis associated in colorectal cancer 1 (MACC1) mRNA expression in vestibular schwannoma
Management of Vestibular Schwannoma: Impact of cranial nerve deficits on the QoL
Pharmaceutical Screening in vestibular schwannoma ex vivo tumor slice model
CAR-T cells against three novel antigens show antitumoral efficacy in ex vivo patient derived glioblastoma organoids
Interdisciplinary treatment & teaching concept in a series of 1,036 vestibular schwannomas
A combination of CAR-T cell specificities can overcome antigen escape mechanisms in ex vivo glioblastoma models
Tumormicroenvironment in Vestibular schwannoma with and without NF2
Metastasis associated in colorectal cancer 1 (MACC1) mRNA expression in vestibular schwannoma
Introducing an innovative and time-effective method to generate ex vivo patient-derived glioblastoma organoid models
Co-culture of PBMCs and patient derived organoids enhances glioblastoma tumor microenvironment
Facial nerve outcome in vestibular schwannomas – which concept holds true at long-term?
Management of Vestibular Schwannoma: Impact of cranial nerve deficits on the QoL
Multi-modality monitoring of auditory function in cerebellopontine angle surgery
Management of Vestibular Schwannoma: The impact of an intermediate nerve disturbance